Mirtazapin Orion (Mirtazapine)

Mirtazapine is used primarily within the antidepressant therapeutic class to address depressive disorders.

• Major Depressive Disorder: reduces depressive symptoms and improves mood in adult patients.
• Generalized Anxiety Disorder (off‑label): may alleviate anxiety symptoms when prescribed by a clinician.
• Bipolar Depression (adjunct): used as an add‑on therapy to manage depressive episodes in bipolar disorder.

• Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, which disinhibits norepinephrine release. It also blocks postsynaptic 5‑HT2 and 5‑HT3 receptors while antagonising 5‑HT1‑A receptors, leading to enhanced serotonergic transmission through 5‑HT1‑A receptors. These combined actions increase noradrenergic and serotonergic neurotransmission, contributing to its antidepressant effect. The drug’s high affinity for these receptors results in a rapid increase in synaptic concentrations of norepinephrine and serotonin, which helps to correct the neurochemical imbalances associated with depressive states.

Mirtazapine may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Sedation or somnolence
• Increased appetite leading to weight gain
• Dry mouth
• Constipation

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia
• Seizures
• Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)

When prescribing Mirtazapin Orion, clinicians should consider several safety measures.

• Monitor weight: regular assessment due to risk of weight gain.
• Assess for sedation: advise caution when operating machinery.
• Screen for hepatic function: periodic liver enzyme tests recommended.
• Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal risk.
• Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Mirtazapin Orion can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis and serotonin syndrome.
• Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome.
• CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.
• CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce efficacy.
• Antihistamines: may enhance sedative effect.